Stock in AVEO Pharmaceuticals Inc. softened following a clinical trial update released in conjunction with the company's full year 2012 earnings. Trial design may have confounded results for tivozanib, which show overall survival (OS) trends favoring the comparator drug Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG), with OS of 28.8 months for tivozanib and 29.3 months for sorafenib (p = 0. 105).